- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03038516
'Palliative-D' Vitamin D to Palliative Cancer Patients (Palliative-D)
'Palliative-D' Vitamin D Supplementation to Palliative Cancer Patients - A Double Blind, Randomised Controlled Trial
연구 개요
상세 설명
PROTOCOL IDENTITY AND OBJECTIVES: EudraCT Number 2017-000268-14 Protocol Title: Vitamin D supplementation to palliative cancer patients - A double blind, randomised controlled trial. Acronym: "Palliative-D" Trial Objectives: To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients can decrease opioid consumption, fatigue and infectious burden and increase quality of life.
INVESTIGATIONAL MEDICINAL PRODUCTS (IMP): Test ProductDetremin, MA holder Renapharma; Pharmaceutical Form: Oil Route of Administration: Oral route
METHODOLOGY Trial Design: Double-blind, parallel randomised and placebo controlled trial Dose/Duration 4000 IU/day for 12 weeks
Primary Endpoint:
The decline of opioid-consumption during 12 weeks in the vitamin D group compared to the placebo group, based on 3 measurements with 4 weeks intervals.
Secondary end Points:
- Decline in antibiotic consumption
- Improvement in quality of life
- Improvement in fatigue
- Vitamin D levels in serum after 12 weeks
- Association between opioid dose and genetic polymorphism in genes involved in the effect and metabolism of vitamin D in the body.
Efficacy Parameters:
Opioid dose, translated to fentanyl per hour measured at baseline and at week 4,8 and 12.
Antibiotic consumption expressed as % of days with antibiotics during the last 4 weeks measured at baseline and at week 4, 8 and 12.
Quality of Life measured with EORTC-QLQ-C15-PAL at baseline and after 12 weeks. Fatigue measured with EORTC-QLQ-C15-PAL at baseline and after 12 weeks. 25-hydroxyvitamin D levels in blood at baseline and after 12 weeks. ESAS (Edmonton Symptom Assessment Scale ) measured at baseline and at week 4, 8 and 12.
Safety Parameters: S-calcium will be controlled in all subjects at baseline, at week 4, 8 and 12 and U-calcium in selected cases Power: The least clinically meaningful effect is estimated to be a 20% decline in opioid dose compared to the placebo. To obtain this result with 80% power the number of patients is estimated to be 127 in each arm i.e. 254 patients in total. This includes a drop-out of 25% per group.
Statistical Analyse plan: The primary endpoint will be analysed using linear regression, using bias corrected and accelerated bootstrap confidence intervals, while controlling for baseline measure of opioid dose (similar to ANCOVA). Adjustment for other background variables - such as vitamin D-level at baseline, gender and age - will be made in a secondary analysis to gain efficiency. The continuous secondary endpoints will be analysed using the same method as the primary endpoint .
POPULATION OF TRIAL SUBJECTS Number of Subjects: 254 (127 vitamin D and 127 placebo) Description of Trial Subjects: Palliative Cancer Patients (any cancer form) with a life expectancy of more than 3 months.
TRIAL TIMETABLE First Subject In Aug 2017 Last Subject In Sept 2019 (25 months to include participants) Last Subject Out Dec 2019 End of intervention Dec 2019 End of follow up Dec2019 End of Trial: Dec 2020
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Stockholm, 스웨덴, 11219
- Stockholms Sjukhem ASIH
-
Älvsjö, 스웨덴, 12559
- ASIH Stockholm Södra
-
-
Stockholm
-
Solna, Stockholm, 스웨덴, 171 54
- ASIH Stockholm Norr
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients admitted to ASIH Stockholm Södra or Stockholms Sjukhem.
- Incurable cancer patients with any type of cancer. They could have ongoing oncological treatment but only with palliative intention. No patients with ongoing oncological treatment with curative intended treated will be included.
- The life expectancy should be at least 3 months according to the clinical assessment of the study physician at the screening visit.
- The patient should have no cognitive failure, being able to comprehend oral and written information about the study.
- 25 OHD < 50 nmol/L.
- Men and women aged ≥18
- Signed 'informed consent'
Exclusion Criteria:
- Ongoing vitamin D supplementation at the time for inclusion.
- Serum level of 25-OH vitamin D3 >50 nmol/L
- Known sarkoidosis
- Treatment with tiazides or digoxin or digitoxin
- Primary hyperparathyroidism
- Hypercalcaemia (verified by a laboratory result younger than 2 month)
- Plans to leave the Stockholm county within 12 weeks of inclusion
- History of kidney stones
- Taking part of another clinical study involving drugs
- Hypersensitivity to cholecalciferol and/or any of the excipients
- Other criteria that could jeopardize the study or its intention as judged by the investigator
- Not being able to perform EORTC-QLQ-C15-PAL or ESAS
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
활성 비교기: Vitamin D
Cholecalciferol (Detremin) solved in MIGLYOL® 812
|
To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.
다른 이름들:
|
위약 비교기: Placebo
MIGLYOL® 812
|
To test the hypothesis that placebo is inferior to vitamin D treatment during 12 weeks to palliative cancer patients in decreasing opioid consumption,
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Change in opioid dose during 12 weeks
기간: 12 weeks
|
The change in decline of opioid-consumption during 12 weeks in the vitamin D group compared to the placebo group, based on 4 measurements with 4 weeks intervals.
|
12 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Change in Antibiotic Consumption during 12 weeks
기간: 12weeks
|
Change in Antibiotic consumption expressed as % of days with antibiotics during the last 4 weeks measured at baseline and at week 4, 8 and 12.
|
12weeks
|
Change in Quality of life after 12 weeks
기간: 12 weeks
|
Change in Quality of Life measured with EORTC-QLQ-C15-PAL at baseline and after 12 weeks.
|
12 weeks
|
Change in Fatigue after12 weeks
기간: 12 weeks
|
Change in Fatigue measured with EORTC-QLQ-C15-PAL at baseline and after 12 weeks.
|
12 weeks
|
Change in 25-hydroxyvitamin D levels after 12 weeks
기간: 12 weeks
|
Change in 25-hydroxyvitamin D levels in blood at baseline and after 12 weeks.
|
12 weeks
|
Change in Symptom burden during 12 weeks
기간: 12 weeks
|
Change in Symptom burden measured with ESAS (Edmonton Symptom Assessment Scale) at baseline and at week 4, 8 and 12.
|
12 weeks
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Linda Björkhem-Bergman, Assoc Prof, Stockholm Läns Landsting
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
비타민 D 결핍에 대한 임상 시험
-
University of UlsterNorthern Ireland Executive; HSC Public Health Agency완전한
-
University of UlsterDairy Council for Northern Ireland; Agri-food & Biosciences Institute; Center for Nutrition...완전한
-
University of Eastern Finland완전한비타민 D 수용체 표적 유전자 발현 | 혈청 25(OH)D 농도핀란드
-
University of Eastern FinlandDSM Nutritional Products, Inc.완전한비타민 D 수용체 표적 유전자 발현 | 혈청 25(OH)D 농도핀란드
-
Meir Medical Center완전한디지털 스테레오 광 디스크 이미지에서 C/D 비율을 측정하는 새로운 기술 개발 | C/D 측정의 관찰자 내 재현성 | C/D 측정의 관찰자 간 가변성
-
Horopito LimitedAtlantia Food Clinical Trials완전한